Aldosterone does not modify gene expression in human endothelial cells

Hormone and Metabolic Research

Volumn 44, Issue 3, 2012, Pages 234-238

  Verhovez, A ^a   Williams, T A ^a   Morello, F ^a   Monticone, S ^a   Brizzi, M F ^b   Dentelli, P ^b   Fallo, F ^c   Fabris, B ^d   Amenta, F ^e   Gomez Sanchez, C ^f   Veglio, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY OF CAMERINO   (Italy)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

endothelial dysfunction; genomic; mineralocorticoid

Indexed keywords

ALDOSTERONE; GLUCOCORTICOID RECEPTOR; LUCIFERASE; MINERALOCORTICOID RECEPTOR;

ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ENDOTHELIUM CELL; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PLASMID; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ALDOSTERONE; CELL LINE; ENDOTHELIAL CELLS; GENE EXPRESSION; GENES, REPORTER; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MINERALOCORTICOIDS; RECEPTORS, MINERALOCORTICOID;

EID: 84858007458     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1291272     Document Type: Article

References (28)

1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-1295 (Pubitemid 46594773)
2. Mulatero P, Milan A, Williams TA, Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 2006; 4: 75-91 (Pubitemid 43796702)
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palenski J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717 (Pubitemid 29407370)
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321 (Pubitemid 36384098)
5. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-167 (Pubitemid 351159920)
6. Hartig PC, Bobseine KL, Britt BH, Cardon MC, Lambright CR, Wilson VS, Gray LE Jr. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Toxicol Sci 2002; 66: 82-90 (Pubitemid 34202031)
7. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643-650 (Pubitemid 40478331)
8. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102: 1359-1367
9. Robert A. Complete prevention of cerebral accidents in malignant hypertension. Circ Res 1956; 4: 527-532
10. Darrow DC, Miller HC. The production of cardiac lesions by repeated injections of desoxycorticosterone acetate. J Clin Invest 1942; 21: 601-611
11. Still WJ, Dennison SM. The pathogenesis of the glomerular changes in steroid-induced hypertension in the rat. Lab Invest 1969; 20: 249-260
12. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458
13. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237 (Pubitemid 29065665)
14. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836 (Pubitemid 35397623)
15. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810 (Pubitemid 35217013)
16. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597 (Pubitemid 30094728)
17. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109: 2857-2861 (Pubitemid 38780298)
18. Struthers AD. Aldosterone-induced vasculopathy. Mol Cell Endocrinol 2004; 217: 239-241 (Pubitemid 38596648)
19. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-197
20. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, Minami I, Iwashima F, Sakai H, Tateno T, Sato R, Hirata Y. Aldosterone increases osteopontin gene expression in RAEC. Biochem Biophys Res Commun 2005; 336: 163-167 (Pubitemid 41253417)
21. Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, Fukai N, Shichiri M, Hirata Y. Aldosterone induces ACE gene expression via a JAK2-dependent pathway in RAEC. Endocrinology 2005; 146: 3900-3906
22. Nietlispach F, Julius B, Schindler R, Bernheim A, Binkert C, Kiowski W, Brunner-La Rocca HP. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 2007; 50: 82-88 (Pubitemid 46986014)
23. Gunaruwan P, Schmitt M, Taylor J, Lee L, Struthers A, Frenneaux M. Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst 2002; 3: 123-125 (Pubitemid 34966183)
24. Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47: 650-655 (Pubitemid 43740234)
25. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens 2009; 27: 2192-2200
26. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010; 24: 2454-2463
27. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53: 286-290
28. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-1014 (Pubitemid 351397957)